Human herpesvirus vaccines and future directions.
Over the last few years there has been an impressive increase in the virological and immunological tools available to detect both human herpesvirus (HHV) and immune control of replication post-solid organ transplantation. This has allowed a greater appreciation of pathogenesis, studies to be designed to evaluate potential vaccines, new approaches adopted for antiviral deployment and the success of interventions to be judged. This chapter aims to summarize the state-of-the-art in vaccine development and look forward to the role that vaccines, immune monitoring, viral kinetics and new antiherpesvirus agents may play in the future management of HHV infections after transplantation.
Department of Infection, University College London, UK and Department of Microbial and Cellular Sciences, University of Surrey, Guildford, UK. v.emery@ucl.ac.uk
V C
VC
Emery
D000818:Animals; D000998:Antiviral Agents / Q000627:therapeutic use; D003586:Cytomegalovirus Infections / Q000150:complications* / Q000175:diagnosis / Q000517:prevention & control; D006566:Herpesviridae Infections / Q000150:complications* / Q000175:diagnosis / Q000517:prevention & control; D022283:Herpesvirus Vaccines / Q000627:therapeutic use*; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D016219:Immunotherapy, Adoptive / Q000379:methods*; D016377:Organ Transplantation / Q000009:adverse effects*; D011183:Postoperative Complications
D000998:Antiviral Agents; D022283:Herpesvirus Vaccines